Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.70 |
| ▸ | BTK | Q06187 | 5/20 | 0.70 |
| ▸ | JAK3 | P52333 | 5/20 | 0.70 |
| ▸ | JAK2 | O60674 | 5/20 | 0.70 |
| ▸ | JAK1 | P23458 | 3/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.70 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.56 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15453597 | 0.90 | JAK2 (0.72) | EGFRBTKJAK3JAK2JAK1 | |
| SCHEMBL15453489 | 0.84 | EGFR (0.72) | EGFRBTKJAK3JAK2JAK1 | |
| SCHEMBL93511 | 0.83 | EGFR (0.69) | EGFRBTKJAK3JAK2MAP3K7 | |
| SCHEMBL15453409 | 0.82 | EGFR (1.00) | EGFRBTKJAK3JAK2JAK1 | |
| SCHEMBL18018878 | 0.81 | EGFR (0.79) | EGFRBTKJAK3JAK2JAK1 | |
| SCHEMBL15453517 | 0.79 | EGFR (0.45) | EGFRBTKJAK3JAK2JAK1 | |
| SCHEMBL18018877 | 0.79 | MAP3K7 (0.81) | EGFRBTKJAK3JAK2JAK1 | |
| SCHEMBL18018785 | 0.78 | MAP3K7 (1.00) | EGFRBTKJAK3JAK2JAK1 | |
| SCHEMBL18018787 | 0.77 | MAP3K7 (0.77) | EGFRBTKJAK3JAK2JAK1 | |
| SCHEMBL15453528 | 0.75 | EGFR (0.46) | EGFRBTKJAK3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140038981-A1 | NOVEL EGFR MODULATORS AND USES THEREOF | ACEA Therapeutics, Inc. | 2014-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038981-A1 | NOVEL EGFR MODULATORS AND USES THEREOF | EGFR, ERBB2, ERBB3 | EGFR 1/4885BTK 114/4885JAK3 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.